国产午夜福利片1000无码丨人妻国产成人久久av免费高清丨午夜做受视频试看6次丨日韩av不卡一区在线免费观看丨在线观看精品三级欧美

Your Good Partner in Biology Research

重組蛋白

產(chǎn)品名稱 貨號(hào) 規(guī)格
Recombinant Pinctada maxima Uncharacterized protein 3 CSB-YP309303PYQ
CSB-EP309303PYQ
CSB-BP309303PYQ
CSB-MP309303PYQ
CSB-EP309303PYQ-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Nigella sativa Defensin D1 CSB-YP309304NDR
CSB-EP309304NDR
CSB-BP309304NDR
CSB-MP309304NDR
CSB-EP309304NDR-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Venerupis philippinarum Insoluble matrix shell protein 3 CSB-YP309305VAT
CSB-EP309305VAT
CSB-BP309305VAT
CSB-MP309305VAT
CSB-EP309305VAT-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Rana shuchinae Bombesin CSB-YP309306RBG
CSB-EP309306RBG
CSB-BP309306RBG
CSB-MP309306RBG
CSB-EP309306RBG-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Schizosaccharomyces pombe Mitosis inducer protein kinase cdr2 (cdr2), partial CSB-YP309307SXV
CSB-EP309307SXV
CSB-BP309307SXV
CSB-MP309307SXV
CSB-EP309307SXV-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Schizosaccharomyces pombe La protein homolog (sla1) CSB-YP309308SXV
CSB-EP309308SXV
CSB-BP309308SXV
CSB-MP309308SXV
CSB-EP309308SXV-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Schizosaccharomyces pombe Probable phospholipase C20G8.02, mitochondrial (SPAC20G8.02), partial CSB-YP309309SXV
CSB-EP309309SXV
CSB-BP309309SXV
CSB-MP309309SXV
CSB-EP309309SXV-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Schizosaccharomyces pombe Putative inorganic pyrophosphatase C3A12.02 (SPAC3A12.02) CSB-YP309310SXV
CSB-EP309310SXV
CSB-BP309310SXV
CSB-MP309310SXV
CSB-EP309310SXV-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Schizosaccharomyces pombe Uncharacterized protein C57A7.05 (SPAC57A7.05), partial CSB-YP309311SXV
CSB-EP309311SXV
CSB-BP309311SXV
CSB-MP309311SXV
CSB-EP309311SXV-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Schizosaccharomyces pombe Threonine--tRNA ligase, cytoplasmic (ths1), partial CSB-YP309312SXV
CSB-EP309312SXV
CSB-BP309312SXV
CSB-MP309312SXV
CSB-EP309312SXV-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Rhamnogalacturonase A (rhgA) CSB-YP309313DOZ
CSB-EP309313DOZ
CSB-BP309313DOZ
CSB-MP309313DOZ
CSB-EP309313DOZ-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Schizosaccharomyces pombe Ribose-phosphate pyrophosphokinase 4 (prs4) CSB-YP309314SXV
CSB-EP309314SXV
CSB-BP309314SXV
CSB-MP309314SXV
CSB-EP309314SXV-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Schizosaccharomyces pombe Uncharacterized protein C3D6.13c (SPBC3D6.13c), partial CSB-YP309315SXV1
CSB-EP309315SXV1
CSB-BP309315SXV1
CSB-MP309315SXV1
CSB-EP309315SXV1-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Schizosaccharomyces pombe Mitosis protein dim1 (dim1) CSB-YP309316SXV
CSB-EP309316SXV
CSB-BP309316SXV
CSB-MP309316SXV
CSB-EP309316SXV-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Schizosaccharomyces pombe DnaJ homolog 1, mitochondrial (mdj1) CSB-YP309317SXV
CSB-EP309317SXV
CSB-BP309317SXV
CSB-MP309317SXV
CSB-EP309317SXV-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Neurospora crassa Woronin body major protein (hex-1) CSB-YP309318NHA
CSB-EP309318NHA
CSB-BP309318NHA
CSB-MP309318NHA
CSB-EP309318NHA-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Saccharomyces cerevisiae Putative uncharacterized protein YDR417C (YDR417C), partial CSB-YP309319SVG1
CSB-EP309319SVG1
CSB-BP309319SVG1
CSB-MP309319SVG1
CSB-EP309319SVG1-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Saccharomyces cerevisiae Putative uncharacterized protein YDR509W (YDR509W), partial CSB-YP309320SVG1
CSB-EP309320SVG1
CSB-BP309320SVG1
CSB-MP309320SVG1
CSB-EP309320SVG1-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Saccharomyces cerevisiae Putative uncharacterized protein YDR274C (YDR274C) CSB-YP309321SVG
CSB-EP309321SVG
CSB-BP309321SVG
CSB-MP309321SVG
CSB-EP309321SVG-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Schizosaccharomyces pombe Uncharacterized UPF0442 protein C16A10.01 (SPAC16A10.01), partial CSB-YP309322SXV
CSB-EP309322SXV
CSB-BP309322SXV
CSB-MP309322SXV
CSB-EP309322SXV-B
20μg/100μg/1mg(1mg*1 or 500ug*2)

有用資源

什么是重組蛋白?

重組蛋白是一種可操縱的蛋白質(zhì)形式,可以通過多種方式產(chǎn)生大量蛋白質(zhì)、修改基因序列和制造有用的商業(yè)產(chǎn)品。重組蛋白的技術(shù)資源在重組蛋白的開發(fā)過程中,除了表達(dá)系統(tǒng)之外,還面臨著一系列令人困惑的選擇,如表達(dá)載體的選擇、表達(dá)蛋白的長度(全長或部分)、是否帶標(biāo)簽等。在生產(chǎn)重組蛋白時(shí),你必須做出很多決定。如果你選擇的明智,你將獲得高質(zhì)量的重組蛋白,后續(xù)的實(shí)驗(yàn)更有可能成功。但是如果你做了錯(cuò)誤的決定,你可能得不到你所需要的重組蛋白或者重組蛋白的質(zhì)量和純度不符合要求。在這里,來自CUSABIO的蛋白表達(dá)工程師根據(jù)他們開發(fā)重組蛋白的經(jīng)驗(yàn)總結(jié)出了幾個(gè)有用的提示,可以幫助你做出明智的決策。

第一條:重組蛋白的生產(chǎn),在這篇文章中,我們旨在闡明重組蛋白的定義以及如何生產(chǎn)重組蛋白。

第二條:如何選擇合適的表達(dá)載體?

表達(dá)載體是一種DNA分子,它攜帶特定的基因進(jìn)入宿主細(xì)胞,并利用細(xì)胞的蛋白質(zhì)合成機(jī)制來產(chǎn)生由該基因編碼的蛋白質(zhì)。表達(dá)載體可使外源基因在宿主細(xì)胞中高效表達(dá),經(jīng)過多年的發(fā)展,表達(dá)載體已成為一種成熟而受歡迎的生物技術(shù)。在重組蛋白生產(chǎn)過程中是一種基本成分。正如標(biāo)題所示,本文主要總結(jié)了幾個(gè)有用的技巧來選擇合適的表達(dá)載體。

第三條:如何表達(dá)具有生物活性的蛋白質(zhì)?

根據(jù)重組蛋白的不同應(yīng)用,對其生物活性有不同的要求。但是我們?nèi)绾未_保蛋白質(zhì)的產(chǎn)生具有生物活性呢?本文將圍繞這個(gè)主題,并提供一些解決方案。除了以上文章,我們還收集了一些重組蛋白的常見問題。您可以單擊以下鏈接查看。http://www.jhhuazhong.com/technology-91.html。此外,我們還為我們的客戶提供重組蛋白表達(dá)服務(wù),您可以點(diǎn)擊這里獲取更多信息。注:如果您對CUSABIO的蛋白質(zhì)有任何疑問,涉及到蛋白質(zhì)的價(jià)格、交貨、質(zhì)量等,您可以點(diǎn)擊橙色按鈕為我們在線留言。

引用資料

Recombinant Severe acute respiratory syndrome coronavirus 2 RNA-dependent RNA polymerase(NSP12) cited in "SARS-CoV-2 hijacks cellular kinase CDK2 to promote viral RNA synthesis". Signal transduction and targeted therapy, 2023

Recombinant Mouse Mixed lineage kinase domain-like protein(Mlkl) cited in "OASL phase condensation induces amyloid-like fibrillation of RIPK3 to promote virus-induced necroptosis". Nature cell biology, 2023

Recombinant Mouse Proto-oncogene c-Fos(Fos) cited in "Dihydroartemisinin imposes positive and negative regulation on Treg and plasma cells via direct interaction and activation of c-Fos". Communications biology, 2023

Recombinant Human Keratin, type I cytoskeletal 18(KRT18) cited in "Calcitonin gene-related peptide ameliorates sepsis-induced intestinal injury by suppressing NLRP3 inflammasome activation". International immunopharmacology, 2023

Recombinant Human Protein Wnt-5a (WNT5A) cited in "ATBF1 is a potential diagnostic marker of histological grade and functions via WNT5A in breast cancer". BMC Cancer, 2022

Read More >>